EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD4‐Based Chimeric Antigen Receptor (CAR)‐T Cells With Resistance to HIV‐1 Infection and Enhanced Anti‐HIV Efficacy: Covalent Interaction Between CD4‐CAR and HIV‐1 Envelope Glycoprotein

Yaoxian Lou iD, Xiuting He, Guangming Li, Martin Sikhondze, Jianping Ma, Hongwei Du, Xin Ouyang, Gianpietro Dotti, Mohammad Sajadi iD, Lishan Su

Journal of Medical Virology · 2026-03 · 98 (3)

DOI: 10.1002/jmv.70853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 25.02.2026. Verfasst von Yaoxian Lou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiologyand Immunology, Institute of Human Virology, University of MarylandSchool of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: HIV-1, Receptors, Chimeric Antigen, HIV Infections, CD4 Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health and National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current highly active antiretroviral therapy (HAART or ART) effectively suppresses de novo HIV‐1 infection but fails to eliminate HIV reservoir cells, which leads to rapid viral rebound upon ART cessation. Chimeric antigen receptor (CAR) T cells engineered to target HIV‐1 Env⁺ cells offer a promising strategy to eliminate or control these persistent reservoirs and achieve durable control of HIV‐1 infection. However, a major challenge is the susceptibility of such CAR‐T cells to HIV infection, especially those soluble CD4 (sCD4)‐based CAR‐T cells. In this study, an sCD4‐based CAR incorporating the S85C mutation in the CD4 Ig‐like domain 1 (termed D1C) was engineered to enable disulfide bond formation with the HIV‐1 envelope glycoprotein (Env), thereby reducing viral entry and conferring protection against HIV infection. D1C/sCD4 CAR‐T cells exhibited enhanced T‐cell activation and cytotoxicity in response to Env stimulation while demonstrating resistance HIV‐1 infection in vitro and in vivo. Furthermore, the herpesvirus entry mediator (HVEM) intracellular domain was identified as an optimal costimulatory domain, enhancing cytokine induction, cytotoxicity, and promoting a favorable central memory phenotype and persistence of CAR‐T cells. In humanized mouse models, D1C/sCD4 CAR‐T cells demonstrated superior persistence and improved control of HIV rebound following ART interruption compared to wild‐type (WT)/sCD4 CAR‐T cells. These findings highlight a novel strategy to enhance the efficacy and durability of HIV‐targeted CAR‐T cell therapy by combining HIV resistance and optimized co‐stimulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Receptors, Chimeric AntigenHIV InfectionsCD4 Antigensenv Gene Products, Human Immunodeficiency VirusCD4-Positive T-LymphocytesHumansAnimalsMiceDisease Models, AnimalImmunotherapy, Adoptive

Stichwörter der Autor:innen

CAR‐THIV resistanceHVEM (TNFRSF14)costimulatory domainhumanized mouse modelsoluble CD4

Substanzen

Receptors, Chimeric AntigenCD4 Antigensenv Gene Products, Human Immunodeficiency Virus

Autor:innen und Institutionen

  • Department of Microbiologyand Immunology, Institute of Human Virology, University of MarylandSchool of Medicine, Baltimore, Maryland, USA.
  • Department of Pharmacology& Physiology, Institute of HumanVirology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of MarylandSchool of Medicine, Baltimore, Maryland, USA.
  • Department of Microbiologyand Immunology, Lineberger ComprehensiveCancer Center, The University of NorthCarolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Medicine, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Yaoxian Lou, Mohammad Sajadi

Förderung

  • National Institutes of Health and National Cancer Institute

Zitieren

APA

Lou, Y., He, X., Li, G., Sikhondze, M., Ma, J., Du, H., Ouyang, X., Dotti, G., Sajadi, M., & Su, L. (2026). CD4‐Based Chimeric Antigen Receptor (CAR)‐T Cells With Resistance to HIV‐1 Infection and Enhanced Anti‐HIV Efficacy: Covalent Interaction Between CD4‐CAR and HIV‐1 Envelope Glycoprotein. Journal of Medical Virology, 98(3). https://doi.org/10.1002/jmv.70853

Vancouver

Lou Y, He X, Li G, Sikhondze M, Ma J, Du H, et al. CD4‐Based Chimeric Antigen Receptor (CAR)‐T Cells With Resistance to HIV‐1 Infection and Enhanced Anti‐HIV Efficacy: Covalent Interaction Between CD4‐CAR and HIV‐1 Envelope Glycoprotein. Journal of Medical Virology. 2026;98(3). doi:10.1002/jmv.70853

BibTeX
@article{Lou2026,
  author = {Lou, Yaoxian and He, Xiuting and Li, Guangming and Sikhondze, Martin and Ma, Jianping and Du, Hongwei and Ouyang, Xin and Dotti, Gianpietro and Sajadi, Mohammad and Su, Lishan},
  title = {CD4‐Based Chimeric Antigen Receptor (CAR)‐T Cells With Resistance to HIV‐1 Infection and Enhanced Anti‐HIV Efficacy: Covalent Interaction Between CD4‐CAR and HIV‐1 Envelope Glycoprotein},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {3},
  doi = {10.1002/jmv.70853}
}
Kostenlos starten →